Collaboration aims to support clinical development of platform designed to reach hard-to-access olfactory region

Kindeva and Canadian tech-health company Rocket Science Health (RSH) have announced a new partnership to advance an intranasal delivery platform designed to target the olfactory clefts — a difficult-to-reach region of the nasal cavity with potential for central nervous system drug delivery.

Under a non-exclusive agreement, the two companies will jointly seek partners to support development of the ‘RSH Olfactory Delivery Device’. The platform is engineered to overcome limitations of conventional nasal sprays by using a laminar stream and proprietary tip design that extends beyond the nasal valve to enable more precise dosing.

Early research indicates that the device may offer improved deposition in the olfactory cleft region, which is being explored for targeted therapies, including those acting via the CNS. The design also emphasises ease of use and human factor integration, aiming to improve accessibility for cognitively or physically impaired patients and support self-administration.

“Our work rethinks intranasal delivery from first principles, including both fluid dynamics and usability,” said Kenneth Irving, founder and CEO of Rocket Science Health. “The goal is to open new frontiers in dose-dependent medicine, particularly for organ systems accessible via the nasal route.”

Kindeva, a global CDMO specialising in complex drug-device combinations, will support Rocket Science Health in identifying partners, progressing the technology toward clinical trials, and navigating regulatory pathways. The collaboration is positioned to accelerate commercial readiness as the device moves closer to human testing.

David Stevens, chief commercial and operating officer at Kindeva, said: “We’re excited to support Rocket Science Health as they bring this innovation into the clinic. Precision intranasal delivery is a growing area of interest, and we believe this platform has the potential to make a significant impact.”